Literature DB >> 28124743

[CRISPR-Cas system as molecular scissors for gene therapy].

G A Heinz1, M-F Mashreghi2.   

Abstract

Since the discovery of the CRISPR-Cas system as the adaptive immune system of prokaryotes, the underlying mechanism has proven to be a precise molecular tool for the targeted editing of genetic information in various cell types. By using the CRISPR-Cas9 system DNA sequences can be cut out at any site in the genome and changed in a sequence-specific manner. In the long term this provides the opportunity to cure diseases caused by gene mutations.

Keywords:  CRISPR-Cas9; Gene mutations; Genome; Immune system; Prokaryotes

Mesh:

Year:  2017        PMID: 28124743     DOI: 10.1007/s00393-017-0267-7

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  13 in total

1.  Introducing precise genetic modifications into human 3PN embryos by CRISPR/Cas-mediated genome editing.

Authors:  Xiangjin Kang; Wenyin He; Yuling Huang; Qian Yu; Yaoyong Chen; Xingcheng Gao; Xiaofang Sun; Yong Fan
Journal:  J Assist Reprod Genet       Date:  2016-04-06       Impact factor: 3.412

2.  CRISPR gene-editing tested in a person for the first time.

Authors:  David Cyranoski
Journal:  Nature       Date:  2016-11-24       Impact factor: 49.962

Review 3.  Exploring the potential of genome editing CRISPR-Cas9 technology.

Authors:  Vijai Singh; Darren Braddick; Pawan Kumar Dhar
Journal:  Gene       Date:  2016-11-09       Impact factor: 3.688

4.  Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy.

Authors:  Chengzu Long; Leonela Amoasii; Alex A Mireault; John R McAnally; Hui Li; Efrain Sanchez-Ortiz; Samadrita Bhattacharyya; John M Shelton; Rhonda Bassel-Duby; Eric N Olson
Journal:  Science       Date:  2015-12-31       Impact factor: 47.728

5.  In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy.

Authors:  Christopher E Nelson; Chady H Hakim; David G Ousterout; Pratiksha I Thakore; Eirik A Moreb; Ruth M Castellanos Rivera; Sarina Madhavan; Xiufang Pan; F Ann Ran; Winston X Yan; Aravind Asokan; Feng Zhang; Dongsheng Duan; Charles A Gersbach
Journal:  Science       Date:  2015-12-31       Impact factor: 47.728

6.  Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients.

Authors:  Gerald Schwank; Bon-Kyoung Koo; Valentina Sasselli; Johanna F Dekkers; Inha Heo; Turan Demircan; Nobuo Sasaki; Sander Boymans; Edwin Cuppen; Cornelis K van der Ent; Edward E S Nieuwenhuis; Jeffrey M Beekman; Hans Clevers
Journal:  Cell Stem Cell       Date:  2013-12-05       Impact factor: 24.633

7.  Multiplex genome engineering using CRISPR/Cas systems.

Authors:  Le Cong; F Ann Ran; David Cox; Shuailiang Lin; Robert Barretto; Naomi Habib; Patrick D Hsu; Xuebing Wu; Wenyan Jiang; Luciano A Marraffini; Feng Zhang
Journal:  Science       Date:  2013-01-03       Impact factor: 47.728

8.  RNA-guided human genome engineering via Cas9.

Authors:  Prashant Mali; Luhan Yang; Kevin M Esvelt; John Aach; Marc Guell; James E DiCarlo; Julie E Norville; George M Church
Journal:  Science       Date:  2013-01-03       Impact factor: 47.728

9.  CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes.

Authors:  Puping Liang; Yanwen Xu; Xiya Zhang; Chenhui Ding; Rui Huang; Zhen Zhang; Jie Lv; Xiaowei Xie; Yuxi Chen; Yujing Li; Ying Sun; Yaofu Bai; Zhou Songyang; Wenbin Ma; Canquan Zhou; Junjiu Huang
Journal:  Protein Cell       Date:  2015-04-18       Impact factor: 14.870

Review 10.  CRISPR-Cas: biology, mechanisms and relevance.

Authors:  Frank Hille; Emmanuelle Charpentier
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2016-11-05       Impact factor: 6.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.